Jiangsu Key Laboratory for Pharmacolgy and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Zhejiang CN Strong Pharmaceutical Co., Ltd., Hangzhou 310000, China.
Int J Mol Sci. 2019 Jan 8;20(1):195. doi: 10.3390/ijms20010195.
Major depressive disorder is now becoming a common disease in daily life, and most patients do not have satisfactory treatment outcomes. We herein evaluated the therapeutic effects of Zhile capsule and clarified the molecular mechanism. A rat model of chronic unpredictable mild stress-induced depression was established to assess the antidepressant-like effects of Zhile by using the sucrose preference test, open field test, forced swim test, tail suspension test and HPLC. Systems pharmacology was then performed to unravel the underlying mechanism which was confirmed by western blot, enzyme-linked immunosorbent assay, and qPCR. Zhile alleviated depression-like behaviors by upregulating the cAMP-CREB-BDNF (brain-derived neurotrophic factor) axis to exert neuroprotective effects. It may be beneficial to depressive patients in clinical practice.
重度抑郁症现在在日常生活中变得越来越常见,大多数患者的治疗效果并不令人满意。我们在此评估了智乐胶囊的治疗效果,并阐明了其分子机制。通过蔗糖偏好测试、旷场测试、强迫游泳测试、悬尾测试和 HPLC,建立了慢性不可预测轻度应激诱导的抑郁大鼠模型,以评估智乐的抗抑郁样作用。然后进行系统药理学研究,通过 Western blot、酶联免疫吸附测定和 qPCR 验证了潜在机制。智乐通过上调 cAMP-CREB-BDNF(脑源性神经营养因子)轴发挥神经保护作用,从而缓解抑郁样行为。它可能对临床实践中的抑郁患者有益。